-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
There are many reasons for the lack of effective treatment for advanced multiple sclerosis.
pathophysiology of advanced multiple sclerosis is not yet known, and no animal model can accurately simulate the entire process of the disease.
therefore, the discovery of new targets and drugs is challenging.
drug reuse is a faster way to have fewer obstacles before entering clinical trials, but the rationale behind drug selection needs to be carefully considered.
this paper establishes a rigorous, expert-led, evidence-based approach to evaluating licensed drugs for reuse and testing in clinical trials of patients with multiple sclerosis (MS).
: Lists licensed drugs that have been approved by expert groups and patients with multiple sclerosis.
we systematically reviewed the preclinical and clinical literature for each drug and, by scoring each compound, condensed it into a database of abstract documents and shortlisted drugs.
the drug in a clinical trial and reviewed our options through a final independent expert review.
results: Four treatment options, namely R-α-sulphate, metformin, R-α-thioic acid and metformin, were recommended from a short list of 55 courses of treatment, as well as niphosphonate.
also gave priority to chromastin, lamotrigine, oxycasipine, nimodypine and fluorocarbons.
drug thioic acid, which is ranked No. 1 in the drug selection program, was also listed as a priority in the 2011 drug selection plan, although the methods were different.
Three interventions, R-α-sulphate, metformin and nihilate, as well as a joint preparation of metformin and R-α-thioic acid, were identified as priority drugs for clinical evaluation in the queue of patients with advanced multiple sclerosis, and there was sufficient data to enter phase II trials immediately.
, Lamotrigine, Okasipine, Nimodipine and fluorocaride are also considered promising and prioritized.
this paper, a standardized method is reported to identify candidate drugs for the treatment of advanced multiple sclerosis.
Cunningiffe N, Vuong KA, Ainslie D, et al System approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis Journal of Neurology, Neurosurgery and Psython Published Online First: 12 November 2020. doi:10.1136/jnnp-2020-324286MedSci Original Source: MedSci Original Copyright Notice: All notes on this website "Source: Met Medical" or "Source: MedSci Original" text, images and audio and video materials, copyrighted by Mace Medical, not authorized No media, website or individual may be reproduced, and authorization must be made with the "Source: Metz Medicine" in the authorizing the reprint.
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here